NeOnc Technologies (NTHI) announced it has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTHI:
- NeOnc Technologies to be featured on ‘Health Uncensored with Dr. Drew’
- NeOnc Technologies Advances to Phase II Brain Cancer Trial
- NeOnc receives FDA authorization to proceed with Phase II trial of NEO212
- NeOnc closes strategic acquisition of advanced AI, 3D bioprinting IP
- NeOnc Completes Acquisition and Board Reshuffle